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MALT1 biology
Since  its  identification  a  decade  ago, 
MALT1 has emerged as a critical me-
diator of T and B cell receptor signal-
ing (Uren et al., 2000; Thome, 2008). 
MALT1 constitutively associates with a 
CARD-containing protein called Bcl-10. 
After  antigen  receptor  engagement,   
the CARD-containing scaffold adaptor 
protein CARMA1/CARD11 is phos-
phorylated by protein kinase C (PKC 
or PKC), allowing MALT1/BCL-10 
to bind (Fig. 1; Rawlings et al., 2006; 
Thome,  2008).  The  subsequent  re-
cruitment of TRAF6 and Nemo/IKK 
to  the  complex  results  in  NF-B– 
dependent gene transcription, which is 
necessary  for  lymphocyte  activation 
(Rawlings et al., 2006; Thome, 2008). 
Studies using gene-targeted mice reveal 
the  functional  importance  of  the 
CARMA1–Bcl-10–MALT1  complex 
in  the  adaptive  immune  response,  as 
lymphocytes  from  mice  deficient  in 
any one of these proteins exhibit defec-
tive proliferation and cytokine produc-
tion upon antigen receptor engagement 
caused by defective NF-B activation 
(Ruland  et  al.,  2001,  2003;  Egawa   
et al., 2003; Hara et al., 2003; Newton 
and Dixit, 2003; Ruefli-Brasse et al., 
2003). The central role of MALT1 in 
regulating  NF-B  activation  is  high-
lighted by the functional consequences 
of  the  chromosomal  translocation 
t(11;18)(q21;q21),  which  is  found  in 
MALT lymphomas. This translocation 
produces a protein consisting of the   
N-terminal portion of cellular inhibitor 
of apoptosis 2 (c-IAP2) fused to the 
immunoglobulin (Ig)-like and caspase-
like segments of MALT1 (Akagi et al., 
1999; Dierlamm et al., 1999). Expres-
sion of the fusion protein leads to con-
stitutive  activation  of  the  NF-kB 
pathway, positioning MALT1 as a po-
tential key factor in the development 
of  inflammation-associated  tumors 
(Uren et al., 2000; Lucas et al., 2001). 
On p. 2313 of this issue, Ferch et al. 
(2009)  demonstrate  that  the  MALT1 
substrates A20 and BCL-11 are consti-
tutively processed in activated B cell–
like  diffuse  large  B  cell  lymphoma 
(ABC-DLBCL)  cells,  exposing  the 
protease activity of MALT1 as an at-
tractive  pharmacological  target  for 
treating these lymphomas.
MALT1-mediated signaling
MALT1 possesses an N-terminal death 
domain, two Ig-like domains, a cen-
trally located caspase-like domain, and 
another Ig-like domain at its C termi-
nus (Fig. 2). The presence of multiple 
protein  interaction  domains  enables 
MALT1 to engage with many poten-
tial  binding  partners.  In  addition  to 
forming  a  constitutive  complex  with 
Bcl-10,  MALT1  also  binds  TRAF6 
and Nemo (Thome, 2008). Its associa-
tions with TRAF6 and/or Nemo are 
postulated  to  promote  ubiquitination 
events that are essential for NF-B ac-
tivation.  Spatiotemporal  models  of 
these  interactions  invoke  MALT1- 
dependent recruitment and oligomer-
ization  of  TRAF6  to  promote 
autoubiquitination of TRAF6 and/or 
ubiquitination of Nemo, Bcl-10, and 
MALT1, as well as the ubiquitin ligase 
activity  of  MALT1  itself  (Thome, 
2008). Thus, ubiquitination is accepted 
as  a  critical  component  of  MALT1-
mediated NF-B activation.
When the caspase-like domain of 
MALT1  was  first  reported,  it  was 
noted that it closely resembled meta-
caspases present in plants and single-
cell organisms (Uren et al., 2000). In 
the years following, there were unsuc-
cessful attempts to show a caspase-like 
activity  for  MALT1  (Snipas  et  al., 
2004). Because mutations in the pre-
dicted active site cysteine greatly di-
minished  the  ability  of  MALT1  to 
induce  NF-B  activation,  it  was 
tempting to suspect that this protein 
harbored  enzymatic  activity  (Lucas   
et al., 2001; Uren et al., 2000). The co-
nundrum was resolved last year when 
two groups identified Bcl-10 and the 
ubiquitin-editing enzyme A20 as sub-
strates  for  MALT1  protease  activity 
(Coornaert  et  al.,  2008;  Rebeaud   
et al., 2008). A20 inhibits NF-B activa-
tion (Malynn and Ma, 2009), so its 
cleavage  by  MALT1  could  diminish 
those inhibitory effects and result in 
persistent  NF-B  activation.  Like-
wise, MALT1-dependent cleavage of 
Bcl-10  controls  integrin-dependent   
T cell activation, and silencing either 
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dependent  arginine-directed  protease 
activity warrants consideration as a thera-
peutic target (Coornaert et al., 2008; 
Rebeaud et al., 2008). Cleavage of Bcl-
10 and A20 in the presence of candidate 
proteins  could  provide  an  efficient 
screening  assay  to  facilitate  drug  dis-
covery. In addition, the small inhibitory 
peptide reported to abolish MALT1 pro-
teolytic activity and MALT1-dependent 
NF-B activation (Rebeaud et al., 2008; 
Ferch et al., 2009) is available as a posi-
tive control for these screens (because 
of their inherent proteolytic susceptibil-
ity and short systemic half-life, such 
small inhibitory peptide are not suitable 
as therapeutic agents).
However, there are several hurdles 
in specifically targeting MALT1 prote-
ase therapeutically, including its valida-
tion as a suitable target. The generation 
of  a  gene-targeted  mouse  expressing 
only  catalytically  inactive  MALT1 
would accomplish this. The phenotype 
of this animal would prove definitively 
whether  MALT1  protease  activity  is 
necessary  for  antigen  receptor–medi-
ated NF-B signaling and the develop-
ment of B cell lymphomas. The caveat 
of the studies published to date is that 
the  MALT1  catalytic  mutant  has  not 
been examined in the complete absence 
of endogenous wild-type MALT1. For 
example, studies reporting the cleavage 
of Bcl-10 and A20 showed that inhibi-
tion of MALT1 proteolytic activity,   
either with small peptide inhibitors or 
active site mutation, resulted in an in-
complete blockade in antigen receptor–
stimulated signaling (Coornaert et al., 
2008; Rebeaud et al., 2008). The resid-
ual  presence  of  endogenous  MALT1 
caused by incomplete small interfering 
(si)  RNA  silencing  or  by  suboptimal 
pharmacokinetic properties of the small 
peptide inhibitors may explain the par-
tial  effect,  but  a  catalytically  inactive 
MALT1 knockin mouse would directly 
address this uncertainty.
Another  missing  link  for  effective 
targeting of MALT1 protease activity is 
the  absence  of  structural  data  on  the 
caspase-like domain (Uren et al., 2000), 
which  imposes  limitations  for  small 
molecule development and hinders op-
timization of initial “hits.” The benefits 
activation,  cytokine  production,  and 
proliferation after antigen receptor en-
gagement  (Ruefli-Brasse  et  al.,  2003; 
Ruland et al., 2003; Ferch et al., 2007). 
This makes it an attractive target for the 
treatment of cancers in which NF-B 
dysregulation is a hallmark of disease. 
Second, MALT1-null animals are fer-
tile and generally healthy (Ruefli-Brasse 
et al., 2003; Ruland et al., 2003), indi-
cating  that  neutralization  of  MALT1 
may be safely tolerated. Finally, MALT1 
plays a prominent role in lymphomas. 
As mentioned, it is a target of chromo-
somal  translocations  associated  with 
MALT lymphomas (Akagi et al., 1999; 
Dierlamm et al., 1999), and its central 
role in regulating the growth of ABC-
DBCLs  is  confirmed  in  this  issue  by 
Ferch et al. (2009; Ngo et al., 2006). 
Thus, its elevated expression in many 
lymphatic malignancies, its central role 
regulating the NF-B survival pathway, 
and the identification of a tumor sup-
pressor (A20) as one of its major sub-
strates  makes  MALT1  an  attractive 
target in cancer therapy.
High hopes for protease inhibitors
Given the role of MALT1 in certain 
lymphoid  malignancies,  its  cysteine- 
protein  diminishes  activation-induced 
adhesion  of  T  cells  (Rebeaud  et  al., 
2008).  Therefore,  Bcl-10  cleavage  by 
MALT1  could  attenuate  integrin- 
dependent adhesion of MALT lympho-
mas. The mechanistic aspects of these 
proteolytic events need further exami-
nation, but they seem to play an im-
portant  role  in  MALT1-dependent 
NF-B  activation  and  cellular  pro-
liferation. In the new study, Ferch et al. 
(2009) demonstrate that ABC-DLBCL 
cells  contain  preassembled  MALT1–
Bcl-10–CARMA1 complexes and con-
stitutively process the MALT1 substrates 
BCL-10 and A20. This finding suggests 
a growth-promoting role for MALT1 
in these lymphomas.
Central regulators make attractive 
therapeutic targets
Although the critical role of MALT1 in 
the  generation  and  progression  of 
MALT lymphomas is well established, 
it has not been not apparent if or how 
MALT1 could be targeted for antican-
cer therapy. However, its attractiveness 
as a potential candidate drug target is 
revealed in several studies. First, gene 
ablation  studies  in  mice  show  that 
MALT1 is a key mediator of NF-B 
Figure 1.  The role of MALT1 in antigen receptor-stimulated activation of NF-B pathway. 
The engagement of antigen receptors results in the activation of protein kinase C (PKC or PKC), 
which leads to phosphorylation and a conformational change of the scaffold adaptor protein 
CARMA1. This change allows the formation of a signaling complex consisting of CARMA1, Bcl-10, 
and MALT1, and enables recruitment of TRAF6 and Nemo, leading to the stimulation of NF-B and B 
cell and T cell activation.JEM VOL. 206, October 26, 2009 2311
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vivo  half-life  of  antisense  oligonucle-
otides (Tamm, 2006).
The fascinating aspect of MALT1 is 
its uniqueness. Most proteins belong to 
a family or to a structurally or function-
ally related group of proteins. However, 
MALT1 is the sole human paracaspase, 
suggesting that MALT1-targeting mol-
ecules may be remarkably specific, al-
though experimental verification of such 
an assumption is lacking at the present 
time.
Overall, the prominent expression 
of MALT1 in lymphatic malignancies, 
together with its critical role in the reg-
ulation of survival signaling pathways, 
makes MALT1 a potentially attractive 
target  for  the  development  of  novel 
cancer therapeutics. A deeper mecha-
nistic understanding of MALT1 should 
enable identification of a therapeutically 
efficacious inhibitor.
We thank Kim Newton for critical reading of the 
manuscript and Allison Bruce for assistance with 
images.
REFERENCES
Akagi, T., M. Motegi, A. Tamura, R. Suzuki, Y. 
Hosokawa, H. Suzuki, H. Ota, S. Nakamura, 
Y. Morishima, M. Taniwaki, and M. Seto. 
1999. A novel gene, MALT1 at 18q21, is 
involved in t(11;18) (q21;q21) found in low-
grade B-cell lymphoma of mucosa-associated 
lymphoid  tissue.  Oncogene.  18:5785–5794. 
doi:10.1038/sj.onc.1203018
Coornaert,  B.,  M.  Baens,  K.  Heyninck,  T. 
Bekaert, M. Haegman, J. Staal, L. Sun, Z.J. 
Chen, P. Marynen, and R. Beyaert. 2008. 
T cell antigen receptor stimulation induces 
MALT1  paracaspase-mediated  cleavage  of 
the NF-kappaB inhibitor A20. Nat. Immunol. 
9:263–271. doi:10.1038/ni1561
ation as a therapeutic strategy (Oltersdorf 
et al., 2005; Flygare and Vucic, 2009; 
Fuentes et al., 2009). Thus, an alterna-
tive approach would be to determine 
the  key  protein–protein  interactions   
of  MALT1  for  antigen  receptor  sig-
naling.  Although  associations  with 
TRAF6, Nemo and a few other sig-
naling  proteins  have  been  reported, 
interaction with Bcl-10 is undoubtedly 
important for MALT1 function (Fig. 1). 
Without Bcl-10, MALT1 cannot par-
ticipate in B or T cell receptor signal-
ing.  Targeting  the  Bcl-10–MALT1 
interaction  would  require  a  well- 
defined binding interface amenable to 
disruption by small molecules. An ob-
vious exception to this targeting strat-
egy  is  the  c-IAP2/MALT1  fusion 
protein, which constitutively activates 
NF-B in a Bcl-10– and stimulus-in-
dependent fashion (Uren et al., 2000; 
Ruland  et  al.,  2003;  Varfolomeev   
et al., 2006).
Finally, the activity of MALT1 could 
also be blocked using antisense oligonu-
cleotides that down-regulate MALT1 by 
targeting  its  native  mRNA.  Knocking 
down MALT1 expression with siRNA 
or short hairpin RNA impairs cleavage 
of Bcl-10 and A20, subsequently affect-
ing receptor signaling (Coornaert et al., 
2008; Rebeaud et al., 2008). Thus, effi-
cient  silencing  of  MALT1  expression 
could potentially dampen T cell– and B 
cell–mediated NF-B activation and cell 
proliferation.  However,  as  with  other 
strategies, siRNA approaches have sev-
eral technical issues, including poor per-
meability, cellular uptake, and short in 
of structural information are exempli-
fied by the development of IAP antago-
nists. The critical role of IAP proteins 
in  the  inhibition  of  apoptosis,  tumor 
maintenance, and therapeutic resistance 
to  anticancer  agents  were  known  for 
years, but there were no evident tar-
geting strategies. It was a structural dis-
covery that revealed that four amino 
acids  in  the  active  form  of  the  pro-
apoptotic  protein  SMAC  were  suffi-
cient for binding and antagonizing IAP 
proteins. These data enabled the de-
velopment of the high-affinity IAP an-
tagonists that are currently undergoing 
clinical evaluation (Flygare and Vucic, 
2009).  Therefore,  future  structural 
studies on the caspase-like domain of 
MALT1 should be viewed as a priority 
for accelerating development of a po-
tent inhibitor.
Finally, one should consider the his-
toric perspective and the data on target-
ing proteases for drug discovery (Turk, 
2006).  Although  there  are  some  re-
markable success stories, such as inhibi-
tors of angiotensin-converting enzyme, 
there are unfortunately many more tales 
of woe, such as the failed clinical devel-
opment of inhibitors of matrix metallo-
proteases.  Thus,  one  should  be 
extremely  cautious  when  considering 
the development of MALT1 protease 
inhibitors. In addition, although Bcl-10 
and  A20  are  likely  true  targets  for   
the  proteolytic  activity  of  MALT1   
(Coornaert et al., 2008; Rebeaud et al., 
2008; Ferch et al., 2009), there may be 
additional functional targets yet to be 
identified, which may have undesired 
consequences.  Systematic  proteomic 
analysis  for  MALT1  substrates  might 
identify  additional  targets  of  potential 
consequence to the therapeutic index 
of the inhibitor.
Other targeting modalities for MALT1
Conventional wisdom in drug discov-
ery is to inhibit a well-defined activity, 
such as an enzymatic function like a 
protease  activity.  However,  recent 
descriptions  of  small  molecules  that 
antagonize  Bcl-2  and  IAP  proteins 
counter this traditional view and sug-
gest that disruption of protein–protein 
interactions deserves serious consider-
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domain and two Ig-like domains, a centrally located caspase-like domain, and another Ig-like do-
main at the C-terminal end of the molecule. The critical active site residues His415 and Cys464 in 
caspase-like domain and the Bcl-10–interacting region of MALT1 are indicated. Potential MALT1-
targeting strategies involve inhibition of the caspase-like protease activity (1) or inhibition of inter-
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